Phenotypes associated with this allele

• Allele Symbol: Ranbp2^tm1Jvd
• Allele Name: targeted mutation 1, Jan M A van Deursen
• Allele ID: MGI:3800898
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Ranbp2^tm1Jvd/Ranbp2^tm1Jvd	involves: 129/Sv * C57BL/6	MGI:3802801
ht2	Ranbp2^tm1Jvd/Ranbp2^tm1.1Jvd	involves: 129/Sv * C57BL/6	MGI:3802800

Genotype
MGI:3802801

hm1

• Allelic Composition: Ranbp2^tm1Jvd/Ranbp2^tm1Jvd
• Genetic Background: involves: 129/Sv * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

aneuploidy ( J:137482 )

• in about 5% of splenocytes

• also range of aneuploidy broadened

abnormal mitosis ( J:137482 )

• 9% of splenocytes fail to progress from metaphase to anaphase

elevated level of mitotic sister chromatid exchange ( J:137482 )

• in cells in which mitosis proceeds, 28% form chromatin bridges

• small number of cells with more than two bridges between chromosomes

• bridges resolve during telophase or cytokinesis

• no evidence for increased chromosome breakage or end-end fusions

neoplasm

increased tumor incidence ( J:137482 )

• increased incidence of spontaneous tumor development

increased incidence of tumors by chemical induction ( J:137482 )

• dramatic increase in skin tumors within 5 months of treatment with DMBA

• 95% of mice with lung tumors within 5 months of treatment with DMBA

• elevated tumor burden (17/mouse) in mice treated with DMBA

increased hepatocellular carcinoma incidence ( J:137482 )

increased lung carcinoma incidence ( J:137482 )

increased sarcoma incidence ( J:137482 )

decreased tumor latency ( J:137482 )

• shorter latency for spontaneous tumor development

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:137482 )

• dramatic increase in skin tumors within 5 months of treatment with DMBA

• 95% of mice with lung tumors within 5 months of treatment with DMBA

• elevated tumor burden (17/mouse) in mice treated with DMBA

liver/biliary system

increased hepatocellular carcinoma incidence ( J:137482 )

respiratory system

increased lung carcinoma incidence ( J:137482 )

Genotype
MGI:3802800

ht2

• Allelic Composition: Ranbp2^tm1Jvd/Ranbp2^tm1.1Jvd
• Genetic Background: involves: 129/Sv * C57BL/6

cellular

aneuploidy ( J:137482 )

• in about 15% of splenocytes

• also range of aneuploidy broadened

abnormal mitosis ( J:137482 )

• 9% of splenocytes fail to progress from metaphase to anaphase

elevated level of mitotic sister chromatid exchange ( J:137482 )

• in cells in which mitosis proceeds, 30% form chromatin bridges

• small number of cells with more than two bridges between chromosomes

• bridges resolve during telophase or cytokinesis

• no evidence for increased chromosome breakage or end-end fusions

neoplasm

increased tumor incidence ( J:137482 )

• increased incidence of spontaneous tumor development

increased incidence of tumors by chemical induction ( J:137482 )

• dramatic increase in skin tumors within 5 months of treatment with DMBA

• 100% of mice with lung tumors within 5 months of treatment with DMBA

• elevated tumor burden (14/mouse) in mice treated with DMBA

increased hepatocellular carcinoma incidence ( J:137482 )

increased lung carcinoma incidence ( J:137482 )

increased sarcoma incidence ( J:137482 )

decreased tumor latency ( J:137482 )

• shorter latency for spontaneous tumor development

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:137482 )

• dramatic increase in skin tumors within 5 months of treatment with DMBA

• 100% of mice with lung tumors within 5 months of treatment with DMBA

• elevated tumor burden (14/mouse) in mice treated with DMBA

liver/biliary system

increased hepatocellular carcinoma incidence ( J:137482 )

respiratory system

increased lung carcinoma incidence ( J:137482 )